PUBBLICAZIONI:
1. Pacini F, Antonelli A, Lari R, Gasperini L, Baschieri L, Pinchera A. Unsuspected parathyroid cysts diagnosed by measurement of thyroglobulin and parathyroid hormone concentrations in fluid aspirates. Ann Intern Med. 1985 Jun;102(6):793-794.
2. Martino E, Macchia E, Aghini-Lombardi F, Antonelli A, Lenziardi M, Concetti R, Fenzi GF, Baschieri L, Pinchera A. Is humoral thyroid autoimmunity relevant in amiodarone iodine-induced thyrotoxicosis? Clin Endocrinol. 1986;24:627-633.
3. Bartalena L, Martino E, Antonelli A, Pacchiarotti A, Robbins J, Pinchera A. Effect of the antileukemic agent L-asparaginase on thyroxine-binding globulin and albumin synthesis in cultured human hepatoma (HEP G2) cells. Endocrinology. 1986,119(3):1185-1188.
4. Benvenga S, Bartalena L, Antonelli A, Li Calzi L, Di Pasquale G, Trimarchi F, Pinchera A. Radioimmunoassay for human thyroxine-binding prealbumin. Ann Clin Lab Sci. 1986 May-Jun;16(3):231-240.
5. Baschieri L, Antonelli A, Del Guerra P. Therapeutic strategy in thyroid carcinoma. Clin Ter. 1987 Jun 30;121(6):457-465.
6. Antonelli A, Del Guerra P, Baschieri L. Somatostatin-induced changes in the secretion of insulin, glucagon and gastrin in functional hypoglycemia. Minerva Endocrinol. 1987 Oct-Dec;12(4):281-288.
7. Bartalena L, Fenzi G, Vitti P, Tombaccini D, Antonelli A, Macchia E, Chiovato L, Kohn LD, Pinchera A. Interaction of the thyrotropin receptor on rat FRTL-5 thyroid cells with thyrotropin and a thyrotropin-stimulating autoantibody from Graves’ patients. Biochem Biophys Res Commun. 1987 Feb 27;143(1):266-272.
8. Antonelli A, Del Guerra P, Fierabracci A, Gori E, Baschieri L. Effect of salmon calcitonin on symptoms and urinary excretion of 5 hydroxyindoleacetic acid in the carcinoid syndrome. Br Med J (Clin Res Ed). 1987 Oct 17;295(6604):961.
9. Antonelli A, Del Guerra P, Baschieri L. Calcitonin and somatostatin effect in carcinoid syndrome. The Italian Journal of Gastroenterology (Digestive and Liver Diseases). 1988;20:137-139.
10. Baschieri L, Castagna M, Fierabracci A, Antonelli A, Del Guerra P, Squartini F. Distribution of calcitonin- and somatostatin-containing cells in thyroid lymphoma and in Hashimoto’s thyroiditis. Appl Pathol. 1989;7(2):99-104.
11. Donati L, Venturi S, Andreani M, Antonelli A, Gori E, Bertoni F, Pruneti CA, Berrettini S, Bruschini P, Baschieri L. Audiological and neuropsychological development study in a sample of school children from a low-iodine area of the Central Apennines that is endemic for cretinism. Minerva Endocrinol. 1989 Apr-Jun;14(2):99-103.
12. Baschieri L, Antonelli A, del Guerra P, Fialdini A, Gasperini L. Somatostatin effect in postprandial hypoglycemia. Metabolism. 1989 Jun;38(6):568-571.
13. Palla R, Cirami C, Panichi V, Bianchi AM, Parrini M, Barsotti G, Cupisti A, Moriconi L, Puccini R, Paleologo G, Cioni L, Antonelli A, Giusti R, Chimienti S, Cristofano C, Dall’Aglio PP, Tamperi E, Bellucci G, L’Abbate A. Treatment of idiopathic membranous nephropathy (MGN) with high dose intravenous gammaglobulin: Results of a multicenter non-randomized and non-controlled trial. Journal of Nephrology, 4, (4), 1991:211-219.
14. Antonelli A, Saracino A, Alberti B, Melosi A, Cartei F, Lepri A, Laddaga M, Baschieri L. The combined therapy of Basedow’s ophthalmopathy with retrobulbar radiotherapy and i.v. immunoglobulins. The preliminary results. Clin Ter. 1992 Jan;140(1):25-31.
15. Carmassi F, Morale M, Puccetti R, Pistelli F, Palla R, Bevilacqua G, Viacava P, Antonelli A, Mariani G. Efficacy of intravenous immunoglobulin therapy in a case of autoimmune-mediated chronic active hepatitis. Clin Exp Rheumatol. 1992 Jan Feb;10(1):13-17.
16. Antonelli A, Saracino A, Alberti B, Canapicchi R, Cartei F, Lepri A, Laddaga M, Baschieri L. High-dose intravenous immunoglobulin treatment in Graves’ ophthalmopathy. Acta Endocrinol (Copenh). 1992 Jan;126(1):13-23.
17. Antonelli A, Gambuzza C, Bertoni F, Baschieri L. Treatment of the carcinoid syndrome with somatostatin, salmon calcitonin, or octreotide. Clin Ther. 1992 Mar-Apr;14(2):178-184.
18. Antonelli A, Saracino A, Agostini S, Alberti B, Melosi A, Gambuzza C, Avantaggiato G, Baschieri L. Results of high-dose intravenous immunoglobulin treatment of patients with pretibial myxedema and Basedow’s disease. Preliminary findings. Clin Ter. 1992 Sep;141(9 Pt 2):63-68.
19. Antonelli A, Palla R, Casarosa L, Alberti B, Saracino A, Baschieri L. In vitro solubilization of deposits of IgG immune complexes by gamma-globulins in patients with Graves’ disease, Graves’ ophthalmopathy, pretibial myxoedema and Hashimoto’s thyroiditis. Pharmacol Res. 1992 Sep;26 Suppl 2:170-171.
20. Antonelli A, Carmassi F, Neri S, Saracino A, Gambuzza C, Alberti B, Baschieri L. Inappropriate antidiuretic hormone secretion in a patient with systemic sarcoidosis. Recenti Prog Med. 1992 Sep;83(9):492-495.
21. Agostini G, Antonelli A. Intravenous immunoglobulins. General features and the main clinical applications. Clin Ter. 1992 Sep;141(9 Pt 2):17-32.
22. Antonelli A, Agostini G, Agostini S. Preliminary results of intravenous immunoglobulins in treating patients with vasculitis. Clin Ter. 1992 Sep;141(9 Pt 2):33-36.
23. Antonelli A, Alberti B, Melosi A, Saracino A, Agostini S, Gambuzza C, Neri S, Baschieri L. Changes in markers of autoimmunity in patients with Hashimoto thyroiditis treated with intravenous immunoglobulins. Preliminary results. Clin Ter. 1992 Sep;141(9 Pt 2):37-42.
24. Antonelli A, Gambuzza C, Alberti B, Saracino A, Melosi A, Agostini S, Blunda P, Baschieri L. Autoimmune polyendocrine syndrome. Treatment with intravenous immunoglobulins. Clin Ter. 1992 Sep;141(9 Pt 2):43-48.
25. Antonelli A, Melosi A, Saracino A, Alberti B, Agostini S, Neri S, Gambuzza C, Biondi L, Baschieri L. Parameters of organ-specific and non-specific autoimmunity in patients with Basedow’s disease and Basedow’s ophthalmopathy. Changes induced by IVIG treatment. Clin Ter. 1992 Sep;141(9 Pt 2):49-54.
26. Antonelli A, Neri S, Gasperini L, Alberti B, Saracino A, Gambuzza C, Agostini S, Baschieri L. Liver function tests, hepatitis A, B, C markers and HIV antibodies in patients with Basedow’s ophthalmopathy treated with intravenous immunoglobulins. Clin Ter. 1992 Sep;141(9 Pt 2):55-61.
27. Donati L, Antonelli A, Bertoni F, Moscogiuri D, Andreani M, Venturi S, Filippi T, Gasperini L, Neri S, Baschieri L. Clinical picture of endemic cretinism in central Apennines (Montefeltro). Thyroid. 1992; 2 (4):283-290.
28. Baschieri L, Antonelli A. Intravenous immunoglobulin treatment in Graves’ Ophthalmopathy. Acta Endocrinologica 1992; 126:474. Letter.
29. Antonelli A, Gambuzza C, Bertoni F, Baschieri L. Calcitonin, as SMS 201-995, ameliorates the VIPoma syndrome. J Endocrinol Invest. 1993 Jan;16(1):57-59.
30. Antonelli A, Carmassi F, Alberti B, Gambuzza C, Neri S, Saracino A, Baschieri L. Demeclocycline-induced phosphate diabetes in a patient with inappropriate ADH secretion and systemic sarcoidosis. Nephron. 1993;63(2):226-229.
31. Falaschi F, Boraschi P, Antonelli A, Neri S, Bartolozzi C. Diagnosis with high resolution computerized tomography of early asbestos-induced diseases. Radiol Med (Torino). 1993 Sep;86(3):220-226.
32. Miccoli P, Antonelli A, Iacconi P, Alberti B, Gambuzza C, Baschieri L. Prospective, randomized, double-blind study about effectiveness of levothyroxine suppressive therapy in prevention of recurrence after operation: result at the third year of follow-up. Surgery. 1993 Dec;114(6):1097-1101.
33. Antonelli A, Navarranne A, Palla R, Alberti B, Saracino A, Mestre C, Roger P, Agostini S, Baschieri L. Pretibial myxedema and high-dose intravenous immunoglobulin treatment. Thyroid. 1994 Winter;4(4):399-408.
34. Neri S, Antonelli A, Falaschi F, Boraschi P, Baschieri L. Findings from high resolution computed tomography of the lung and pleura of symptom free workers exposed to amosite who had normal chest radiographs and pulmonary function tests. Occup Environ Med. 1994 Apr;51(4):239-243.
35. Alberti B, Campatelli A, Antonelli A, Di Vito A, Francese C, Saracino A, Agostini S, Baschieri L. Review of a case series of cervical cysts and evaluation of the efficacy of sclerotherapy with tetracycline hydrochloride in thyroid cystic lesions. Clin Ter. 1994 Jul;145(7):27-33.
36. Neri S, Antonelli A, Boraschi P, Falaschi F, Rizzini D, Baschieri L. Asbestos-related lesions detected by high-resolution CT scanning in asymptomatic workers. Specificity, relation to the duration of exposure and cigarette smoking. Clin Ter. 1994 Aug;145(8):97-106.
37. Antonelli A, Campatelli A, Di Vito A, Alberti B, Baldi V, Salvioni G, Fallahi P, Baschieri L. Comparison between ethanol sclerotherapy and emptying with injection of saline in treatment of thyroid cysts. Clin Investig. 1994 Dec;72(12):971-974.
38. Antonelli A, Miccoli P, Ferdeghini M, Di Coscio G, Alberti B, Iacconi P, Baldi V, Fallahi P, Baschieri L. Role of neck ultrasonography in the follow-up of patients operated on for thyroid cancer. Thyroid. 1995 Feb;5(1):25-28.
39. Antonelli A, Silvano G, Bianchi F, Gambuzza C, Tana L, Salvioni G, Baldi V, Gasperini L, Baschieri L. Risk of thyroid nodules in subjects occupationally exposed to radiation: a cross sectional study. Occup Environ Med. 1995 Aug;52(8):500-504.
40. Falaschi F, Boraschi P, Neri S, Antonelli A, Rizzini D, Battolla L. High resolution Computed Tomography (HRCT) in the detection of “early asbestosis”. European Radiology. 1995;5:291-296.
41. Falaschi F, Battolla L, Mascalchi M, Cioni R, Zampa V, Lencioni R, Antonelli A, Bartolozzi C. Usefulness of MR signal intensity in distinguishing benign from malignant pleural disease. AJR Am J Roentgenol. 1996 Apr;166(4):963-968.
42. Antonelli A, Silvano G, Gambuzza C, Bianchi F, Tana L, Baschieri L. Is occupationally induced exposure to radiation a risk factor of thyroid nodule formation? Arch Environ Health. 1996 May-Jun;51(3):177-180.
43. Antonelli A, Palla R, Casarosa L, Fallahi P, Baschieri L. IgG, IgA and C3 deposits in the extra-thyroidal manifestations of autoimmune Graves’ disease: their in vitro solubilization by intravenous immunoglobulin. Clin Exp Rheumatol. 1996 May-Jun;14 Suppl 15:S31-35.
44. Iacconi P, Antonelli A, Monzani F, Bendinelli C, Ricci E, Miccoli P. Postoperative organotherapy for multinodular goiter Ann Ital Chir. 1996 May-Jun;67(3):347-350.
45. Antonelli A, Miccoli P, Derzhitski VE, Panasiuk G, Solovieva N, Baschieri L. Epidemiologic and clinical evaluation of thyroid cancer in children from the Gomel region (Belarus). World J Surg. 1996 Sep;20(7):867-871.
46. Falaschi F, Battolla L, Zampa V, Cioni R, Cambi L, Antonelli A, Bartolozzi C. CT versus MRI in the differentiation of benign from malignant pleural disease [Confronto fra tomografia computerizzata e risonanza magnetica nella valutazione delle malattie pleuriche benigne e maligne]. Radiologia Medica (Torino). 1996 Dec;92(6):713-718.
47. Antonelli A, Bombardieri S, Fallahi P, Kotopulos CDA, Battaglia S, Baschieri L. Thyroid and non organ specific autoantibodies in patients with thyroid-associated ophthalmopathy. Orbit. 1996; 15 (3):213-219.
48. Antonelli A, Silvano G, Bianchi F, Gambuzza C, Tana L, Fallahi P, Baschieri L. Reply to the comments on Risk of thyroid nodules in subject occupationally exposed to radiation: a cross sectional study. Occupational and Enviromental Medicine. 1996; 53: 575.
49. Neri S, Boraschi P, Antonelli A, Falaschi F, Baschieri L. Pulmonary function, smoking habits, and high resolution computed tomography (HRCT) early abnormalities of lung and pleural fibrosis in shipyard workers exposed to asbestos. Am J Ind Med. 1996 Nov;30(5):588-95.
50. Neri S, Boraschi P, Antonelli A, Falaschi F, Baschieri L. Pulmonary function, smoking habits, and high resolution computed tomography (HRCT) early abnormalities of lung and pleural fibrosis in shipyard workers exposed to asbestos. Pneumologie. 1997; 51, (4): 351-352. ISI WEB
51. Baschieri L, Antonelli A, Nardi S, Alberti B, Lepri A, Canapicchi R, Fallahi P. Intravenous immunoglobulin versus corticosteroid in treatment of Graves’ ophthalmopathy. Thyroid. 1997 Aug;7(4):579-585.
52. Miccoli P, Antonelli A, Spinelli C, Ferdeghini M, Fallahi P, Baschieri L. Completion total thyroidectomy in children with thyroid cancer secondary to the Chernobyl accident. Arch Surg. 1998 Jan;133(1):89-93.
53. Barale R, Gemignani F, Morizzo C, Lori A, Rossi A, Antonelli A, Di Pretoro G, Panasiuk G, Ballardin M. Cytogenetic damage in lymphocytes of healthy and thyroid tumor-affected children from the Gomel region (Belarus). Mutat Res. 1998 Aug 31;405(1):89-95.
54. Antonelli A, Ferri C, Fallahi P. Thyroid cancer in patients with hepatitis C infection. JAMA. 1999 May 5;281(17):1588.
55. Ferrannini E, Galvan AQ, Gastaldelli A, Camastra S, Sironi AM, Toschi E, Baldi S, Frascerra S, Monzani F, Antonelli A, Nannipieri M, Mari A, Seghieri G, Natali A. Insulin: new roles for an ancient hormone. Eur J Clin Invest. 1999 Oct;29(10):842-852.
56. Pupilli C, Giannini S, Marchetti P, Lupi R, Antonelli A, Malavasi F, Takasawa S, Okamoto H, Ferrannini E. Autoantibodies to CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) in Caucasian patients with diabetes: effects on insulin release from human islets. Diabetes. 1999 Dec;48(12):2309-2315.
57. Gemignani F, Ballardin M, Maggiani F, Rossi AM, Antonelli A, Barale R. Chromosome aberrations in lymphocytes and clastogenic factors in plasma detected in Belarus children 10 years after Chernobyl accident. Mutat Res. 1999 Dec 13;446(2):245-253.
58. Pupilli C, Antonelli A, Marchetti P, Giannini S, Ferrannini E. Anticorpi anti CD38: un nuovo marker di autoimmunità nel diabete mellito con effetti modulatori sulla secrezione insulinica. Il Diabete. 2000; 12: 112-115.
59. Frenzilli G, Bosco E, Antonelli A, Panasiuk G, Barale R. DNA damage evaluated by alkaline single cell gel electrophoresis (SCGE) in children of Chernobyl, 10 years after the disaster. Mutat Res. 2001 Apr 5;491(1-2):139-149.
60. Antonelli A, Baj G, Marchetti P, Fallahi P, Surico N, Pupilli C, Malavasi F, Ferrannini E. Human anti-CD38 autoantibodies raise intracellular calcium and stimulate insulin release in human pancreatic islets. Diabetes. 2001 May;50(5):985-991.
61. Antonelli A, Fallahi P, Nesti C, Pupilli C, Marchetti P, Takasawa S, Okamoto H, Ferrannini E. Anti-CD38 autoimmunity in patients with chronic autoimmune thyroiditis or Graves’ disease. Clin Exp Immunol. 2001 Dec;126(3):426-431.
62. Ferri C, Zignego AL, Giuggioli D, Sebastiani M, Cazzato M, Antonelli A, La Civita L, Fadda P, Longombardo G, Pileri S. HCV and cryoglobulinemic vasculitis. Cleve Clin J Med. 2002;69 Suppl 2:SII20-3.
63. Antonelli A, Tuomi T, Nannipieri M, Fallahi P, Nesti C, Okamoto H, Groop L, Ferrannini E. Autoimmunity to CD38 and GAD in Type I and Type II diabetes: CD38 and HLA genotypes and clinical phenotypes. Diabetologia. 2002 Sep;45(9):1298-1306.
64. Antonelli A, Ferri C, Fallahi P, Nesti C, Zignego AL, Maccheroni M. Thyroid cancer in HCV-related mixed cryoglobulinemia patients. Clin Exp Rheumatol. 2002 Sep-Oct;20(5):693-696.
65. Marchetti P, Antonelli A, Lupi R, Marselli L, Fallahi P, Nesti C, Baj G, Ferrannini E. Prolonged in vitro exposure to autoantibodies against CD38 impairs the function and survival of human pancreatic islets. Diabetes. 2002 Dec;51 Suppl 3:S474-477.
66. Ferri C, Longombardo G, Giuggioli D, Sebastiani M, Cazzato M, La Civita L, Fadda P, Antonelli, A. Cryoglobulinemia [Le crioglobulinemie] Progressi in Reumatologia. 2002; Suppl 3:45-48.
67. Antonelli A, Miccoli P, Fallahi P, Grosso M, Nesti C, Spinelli C, Ferrannini E. Role of neck ultrasonography in the follow-up of children operated on for thyroid papillary cancer. Thyroid. 2003 May;13(5):479-484.
68. Antonelli A, Ferri C, Fallahi P, Sebastiani M, Nesti C, Barani L, Barale R, Ferrannini E. Type 2 diabetes in hepatitis C-related mixed cryoglobulinaemia patients. Rheumatology (Oxford). 2004 Feb;43(2):238-240.
69. Ferri C, Sebastiani M, Giuggioli D, Cazzato M, Longombardo G, Antonelli A, Puccini R, Michelassi C, Zignego AL. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum. 2004 Jun;33(6):355-374.
70. Antonelli A, Ferri C, Pampana A, Fallahi P, Nesti C, Pasquini M, Marchi S, Ferrannini E. Thyroid disorders in chronic hepatitis C. Am J Med. 2004 Jul 1;117(1):10-13.
71. Antonelli A, Ferri C, Fallahi P, Giuggioli D, Nesti C, Longombardo G, Fadda P, Pampana A, Maccheroni M, Ferrannini E. Thyroid involvement in patients with overt HCV-related mixed cryoglobulinaemia. QJM. 2004 Aug;97(8):499-506.
72. Spinelli C, Bertocchini A, Antonelli A, Miccoli P. Surgical therapy of the thyroid papillary carcinoma in children: experience with 56 patients < or =16 years old. J Pediatr Surg. 2004 Oct;39(10):1500-1505.
73. Antonelli A, Ferrannini E. CD38 autoimmunity: recent advances and relevance to human diabetes. J Endocrinol Invest. 2004 Jul-Aug;27(7):695-707.
74. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Buonamano A, Ferrannini E, Serio M. High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab. 2004 Nov;89(11):5496-5499.
75. Santini E, Fallahi P, Ferrari SM, Masoni A, Antonelli A, Ferrannini E. Effect of PPAR-gamma activation and inhibition on glucose-stimulated insulin release in INS-1e cells. Diabetes. 2004 Dec;53 Suppl 3:S79-83.
76. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Paolicchi A, Ferrannini E, Serio M. Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis. Eur J Endocrinol. 2005 Feb;152(2):171-177.
77. Lanni A, Moreno M, Lombardi A, de Lange P, Silvestri E, Ragni M, Farina P, Baccari GC, Fallahi P, Antonelli A, Goglia F. 3,5-diiodo-L-thyronine powerfully reduces adiposity in rats by increasing the burning of fats. FASEB J. 2005 Sep;19(11):1552-1554.
78. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Ferrannini E, Serio M. Age-dependent changes in CXC chemokine ligand 10 serum levels in euthyroid subjects. J Interferon Cytokine Res. 2005 Sep;25(9):547-552.
79. Antonelli A, Ferri C, Fallahi P, Pampana A, Ferrari SM, Goglia F, Ferrannini E. Hepatitis C virus infection: evidence for an association with type 2 diabetes. Diabetes Care. 2005 Oct;28(10):2548-2550.
80. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Ghinoi A, Mascia MT, Ferrannini E. Extrahepatic manifestations of hepatitis C virus: the thyroid disorders. Recenti Prog Med. 2005 Jul-Aug;96(7-8):370-381.
81. Pupilli C, Antonelli A, Iughetti L, D’Annunzio G, Cotellessa M, Vanelli M, Okamoto H, Lorini R, Ferrannini E. Anti-CD38 autoimmunity in children with newly diagnosed type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2005 Dec;18(12):1417-1423.
82. Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, Franceschini SS, Serio M, Ferrannini E. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves’ ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab. 2006 Feb;91(2):614-620.
83. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Barani L, Ferrannini E, Serio M. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves’ disease, and modulation by methimazole therapy. Clin Endocrinol (Oxf). 2006 Feb;64(2):189-195.
84. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Romagnani P, Grosso M, Ferrannini E, Serio M. Increased serum CXCL10 in Graves’ disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur J Endocrinol. 2006 May;154(5):651-658.
85. Antonelli A, Rotondi M, Fallahi P, Ferrari SM, Paolicchi A, Romagnani P, Serio M, Ferrannini E. Increase of CXC chemokine CXCL10 and CC chemokine CCL2 serum levels in normal ageing. Cytokine. 2006 Apr;34(1-2):32-38.
86. Scarpato R, Antonelli A, Ballardin M, Cipollini M, Fallahi P, Tomei A, Traino C, Barale R. Analysis of chromosome damage in circulating lymphocytes of radiological workers affected by thyroid nodules. Mutat Res. 2006 Jul 14;606(1-2):21-26.
87. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Serio M, Miccoli P. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves’ disease, and modulation by methimazole therapy and thyroidectomy. Br J Surg. 2006 Oct;93(10):1226-1231.
88. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Ghinoi A, Rotondi M, Ferrannini E. Thyroid disorders in chronic hepatitis C virus infection. Thyroid. 2006 Jun;16(6):563-572.
89. Antonelli A, Fazzi P, Fallahi P, Ferrari SM, Ferrannini E. Prevalence of hypothyroidism and Graves disease in sarcoidosis. Chest. 2006 Aug;130(2):526-532.
90. Galetta F, Franzoni F, Fallahi P, Rossi M, Carpi A, Rubello D, Antonelli A, Santoro G. Heart rate variability and QT dispersion in patients with subclinical hypothyroidism. Biomed Pharmacother. 2006 Sep;60(8):425-430.
91. Franzoni F, Galetta F, Fallahi P, Tocchini L, Merico G, Braccini L, Rossi M, Carpi A, Antonelli A, Santoro G. Effect of L-thyroxine treatment on left ventricular function in subclinical hypothyroidism. Biomed Pharmacother. 2006 Sep;60(8):431-436.
92. Antonelli A, Delle Sedie A, Fallahi P, Ferrari SM, Maccheroni M, Ferrannini E, Bombardieri S, Riente L. High prevalence of thyroid autoimmunity and hypothyroidism in patients with psoriatic arthritis. J Rheumatol. 2006 Oct;33(10):2026-2028.
93. Rossi M, Galetta F, Franzoni F, Antonelli A, Santoro G. Cardiovascular remodelling in patients with sub-clinical hypothyroidism. Minerva Cardioangiol. 2006 Dec;54(6):807-810.
94. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Goglia F, Ferrannini E. Hepatitis C Virus Infection: Evidence for an Association With Type 2 Diabetes: Response to Skowronski et al. Diabetes Care. 2006 March;29(3):751.
95. Antonelli A, Miccoli P, Fallahi P, Ferrari SM, Grosso M, Boni G, Berti P. Thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma in children. Surgery. 2006 Dec;140(6):1035-1041; discussion 1041-1042.
96. Ballardin M, Antonelli A, Cipollini M, Fallahi P, Scarpato R, Tomei A, Traino C, Barale R. Induction of chromatid-type aberrations in peripheral lymphocytes of hospital workers exposed to very low doses of radiation. Mutat Res. 2007 Jan 10;626(1-2):61-68.
97. Miccoli P, Materazzi G, Antonelli A, Panicucci E, Frustaci G, Berti P. New trends in the treatment of undifferentiated carcinomas of the thyroid. Langenbecks Arch Surg. 2007 Jul;392(4):397-404.
98. Antonelli A, Rotondi M, Fallahi P, Grosso M, Boni G, Ferrari SM, Romagnani P, Serio M, Mariani G, Ferrannini E. Iodine-131 Given for Therapeutic Purposes Modulates Differently Interferon-{gamma}-Inducible {alpha}-Chemokine CXCL10 Serum Levels in Patients with Active Graves’ Disease or Toxic Nodular Goiter. J Clin Endocrinol Metab. 2007 Apr;92(4):1485-1490.
99. Antonelli A, Ferri C, Fallahi P, Cazzato M, Ferrari SM, Sebastiani M, Ferrannini E. Clinical and subclinical autoimmune thyroid disorders in systemic sclerosis. Eur J Endocrinol. 2007 Apr;156(4):431-437.
100. Antonelli A, Ferri C, Fallahi P, Pampana A, Ferrari SM, Barani L, Marchi S, Ferrannini E. Thyroid Cancer in HCV-Related Chronic Hepatitis Patients: A Case-Control Study. Thyroid. 2007 May;17(5):447-451.
101. Carpi A, Nicolini A, Marchetti C, Iervasi G, Antonelli A, Carpi F. Percutaneous large-needle aspiration biopsy histology of palpable thyroid nodules: technical and diagnostic performance. Histopathology. 2007 Aug;51(2):249-257.
102. Ferri C, Antonelli A, Mascia MT, Sebastiani M, Fallahi P, Ferrari D, Giunti M, Pileri SA, Zignego AL. B-cells and mixed cryoglobulinemia. Autoimmun Rev. 2007 Dec;7(2):114-120.
103. Ferri C, Antonelli A, Mascia MT, Sebastiani M, Fallahi P, Ferrari D, Pileri SA, Zignego AL. HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Dig Liver Dis. 2007 Sep;39 Suppl 1:S13-21.
104. Galetta F, Franzoni F, Fallahi P, Tocchini L, Braccini L, Santoro G, Antonelli A. Changes in heart rate variability and QT dispersion in patients with overt hypothyroidism. Eur J Endocrinol. 2008 Jan;158(1):85-90.
105. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Giuggioli D, Colaci M, Manfredi A, Frascerra S, Franzoni F, Galetta F, Ferrannini E. CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis–a longitudinal study. Rheumatology (Oxford). 2008 Jan;47(1):45-49.
106. Antonelli A, Ferri C, Galeazzi M, Giannitti C, Manno D, Mieli-Vergani G, Menegatti E, Olivieri I, Puoti M, Palazzi C, Roccatello D, Vergani D, Sarzi-Puttini P, Atzeni F. HCV infection: pathogenesis, clinical manifestations and therapy. Clin Exp Rheumatol. 2008 Jan-Feb;26(1 Suppl 48):S39-47.
107. Franzoni F, Galetta F, Fallahi P, Tocchini L, Braccini L, Rossi M, Carpi A, Santoro G, Antonelli A. Carotid integrated backscatter analysis in patients with subclinical hypothyroidism. Clin Endocrinol (Oxf). 2008 Feb;68(2):278-283.
108. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Romagnani P, Ghiadoni L, Serio M, Taddei S, Ferrannini E. High serum levels of CXC chemokine ligand 10 in untreated essential hypertension. J Hum Hypertens. 2008 Aug;22(8):579-581.
109. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, Sebastiani M, Franzoni F, Galetta F, Ferrannini E. High values of CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune thyroiditis. Cytokine. 2008 Apr;42(1):137-143.
110. Carpi A, Di Coscio G, Iervasi G, Antonelli A, Mechanick J, Sciacchitano S, Nicolini A. Thyroid fine needle aspiration: How to improve clinicians’ confidence and performance with the technique. Cancer Lett. 2008 Jun 18;264(2):163-171.
111. Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, Marchetti I, Ugolini C, Basolo F, Miccoli P, Ferrannini E. Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration. Eur J Endocrinol. 2008 Sep;159(3):283-291.
112. Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, Barani L, Marchetti I, Ferrannini E, Miccoli P. Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests. Clin Endocrinol (Oxf). 2008 Jul;69(1):148-152.
113. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, Carpi A, Nicolini A, Ferrannini E. Alpha-chemokine CXCL10 and beta-chemokine CCL2 serum levels in patients with hepatitis C-associated cryoglobulinemia in the presence or absence of autoimmune thyroiditis. Metabolism. 2008 Sep;57(9):1270-1277.
114. Antonelli A, Fallahi P, Ferrari SM, Carpi A, Berti P, Materazzi G, Minuto M, Guastalli M, Miccoli P. Dedifferentiated thyroid cancer: A therapeutic challenge. Biomed Pharmacother. 2008 Oct;62(8):559-563.
115. Antonelli A, Ferri C, Ferrari SM, Colaci M, Fallahi P. Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia. Autoimmun Rev. 2008 Oct;8(1):18-23.
116. Antonelli A, Ferri C, Fallahi P, Colaci M, Giuggioli D, Ferrari SM, Frascerra S, Franzoni F, Galetta F, Ferrannini E. Th1 and Th2 Chemokine Serum Levels in Systemic Sclerosis in the Presence or Absence of Autoimmune Thyroiditis. J Rheumatol. 2008 Sep;35(9):1809-1811.
117. Antonelli A, Fallahi P, Tolari S, Ferrari SM, Ferrannini E. Thyroid-associated ophthalmopathy and TSH receptor autoantibodies in nonmetastatic thyroid cancer after total thyroidectomy. Am J Med Sci. 2008 Sep;336(3):288-290.
118. Sebastiani M, Manfredi A, Colaci M, Giuggioli D, La Sala R, Elkhaldi N, Antonelli A, Ferri C. [Correlation of a quantitative videocapillaroscopic score with the development of digital skin ulcers in scleroderma patients]. Reumatismo. 2008 Jul-Sep;60(3):199-205. Italian.
119. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Sebastiani M, Ferrari D, Giunti M, Frascerra S, Tolari S, Franzoni F, Galetta F, Marchi S, Ferrannini E. High Values of CXCL10 Serum Levels in Mixed Cryoglobulinemia Associated With Hepatitis C Infection. Am J Gastroenterol. 2008 Oct;103(10):2488-2494.
120. Antonelli A, Fallahi P, Delle Sedie A, Ferrari SM, Maccheroni M, Bombardieri S, Riente L, Ferrannini E. High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune thyroiditis. Autoimmunity. 2008 Nov;41(7):537-542.
121. Antonelli A, Fallahi P, Ferrari SM, Pupilli C, d’Annunzio G, Lorini R, Vanelli M, Ferrannini E. Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed Type 1 diabetes: a longitudinal study. Diabet Med. 2008 Nov;25(11):1349-1353.
122. Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, Ghiri E, Carpi A, Nicolini A, Miccoli P. Treatment of Anaplastic Thyroid Cancer: Is there a Role for PPARgamma Agonists? Recent Patents on Endocrine, Metabolic & Immune Drug Discovery. 2008 Nov;2(3): 194-199.
123. Fallahi P, Ferri C, Ferrari SM, Pampana A, Sansonno D, Antonelli A. The emerging extrahepatic manifestations of hepatitis C virus infection in chronic hepatitis and mixed cryoglobulinemia. Hepatitis Monthly. 2008; 8(3): 207-211.
124. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, Franzoni F, Galetta F, Zignego AL, Ferrannini E. CXCL10 and CCL2 serum levels in patients with mixed cryoglobulinaemia and hepatitis C. Dig Liver Dis. 2009 Jan;41(1):42-48.
125. Antonelli A, Fazzi P, Fallahi P, Ferrari SM, Grosso M, Boni G, Ferrannini E, Mariani G. Thyroid uptake of (67)Ga-citrate is associated with thyroid autoimmunity and hypothyroidism in patients with sarcoidosis. Eur J Nucl Med Mol Imaging. 2009 Jan;36(1):137-143.
126. Antonelli A, Ferri C, Ferrari SM, Colaci M, Sansonno D, Fallahi P. Endocrine manifestations of hepatitis C virus infection. Nat Clin Pract Endocrinol Metab. 2009 Jan;5(1):26-34.
127. Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, Minuto M, Giannini R, Marchetti I, Barani L, Basolo F, Ferrannini E, Miccoli P. Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells. Clin Endocrinol (Oxf). 2009 Jun;70(6):946-953.
128. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, Pampana A, Panicucci E, Carpi A, Nicolini A, Ferrannini E. CXCL10 and CCL2 chemokine serum levels in patients with hepatitis C associated with autoimmune thyroiditis. J Interferon Cytokine Res. 2009 Jun;29(6):345-51.
129. Antonelli A, Fallahi P, Delle Sedie A, Ferrari SM, Maccheroni M, Bombardieri S, Riente L, Ferrannini E. High values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic arthtritis. Clin Exp Rheumatol. 2009 Jan-Feb;27(1):22-27.
130. Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Santini E, Franceschini SS, Ferrannini E. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves’ disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab. 2009 May;94(5):1803-1809.
131. Mollica MP, Lionetti L, Moreno M, Lombardi A, De Lange P, Antonelli A, Lanni A, Cavaliere G, Barletta A, Goglia F. 3,5-diiodo-l-thyronine, by modulating mitochondrial functions, reverses hepatic fat accumulation in rats fed a high-fat diet. J Hepatol. 2009 Aug;51(2):363-370.
132. Antonelli A, Ferri C, Ferrari SM, Ghiri E, Marchi S, Colaci M, Bruschi F, Fallahi P. High interleukin-6 and tumor necrosis factor-alpha serum levels in hepatitis C infection associated or not with mixed cryoglobulinemia. Clin Rheumatol. 2009 Oct;28(10):1179-1185.
133. Scarpato R, Tusa I, Antonelli A, Fallahi P, Sbrana I. Spontaneous and bleomycin-induced chromosome damage in non cancer thyroid patients. Eur J Clin Invest. 2009 Dec;39(12):1091-1097.
134. Galetta F, Bernini G, Franzoni F, Bacca A, Fivizzani I, Tocchini L, Bernini M, Fallahi P, Antonelli A, Santoro G. Cardiac remodeling in patients with primary aldosteronism. J Endocrinol Invest. 2009 Oct;32(9):739-745.
135. Miccoli P, Miccoli M, Antonelli A, Minuto MN. Clinicopathologic and molecular disease prognostication for papillary thyroid cancer. Expert Rev Anticancer Ther. 2009 Sep;9(9):1261-1275.
136. Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Piaggi S, Gelmini S, Lupi C, Minuto M, Berti P, Benvenga S, Basolo F, Orlando C, Miccoli P. Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists. Endocr Relat Cancer. 2009 Dec;16(4):1299-1311.
137. Antonelli A, Ferri C, Ferrari SM, Galetta F, Franzoni F, Santoro G, De Marco S, Ghiri E, Fallahi P. High circulating N-terminal pro-brain natriuretic peptide and tumor necrosis factor-alpha in mixed cryoglobulinemia. World J Gastroenterol. 2009 Oct 28;15(40):5074-5079.
138. Antonelli A, Ferri C, Fallahi P. Hepatitis C: thyroid dysfunction in patients with hepatitis C on IFN-alpha therapy. Nat Rev Gastroenterol Hepatol. 2009 Nov;6(11):633-635.
139. Carpi A, Nicolini A, Antonelli A, Ferrari P, Rossi G. Cytokines in the management of high risk or advanced breast cancer: an update and expectation. Curr Cancer Drug Targets. 2009 Dec;9(8):888-903.
140. Antonelli A, Ferri C, Ferrari SM, Ghiri E, Galetta F, Franzoni F, Santoro G, Fallahi P. High circulating levels of N-terminal pro-brain natriuretic peptide and interleukin 6 in patients with mixed cryoglobulinemia. J Med Virol. 2010 Feb;82(2):297-303.
141. Antonelli A, Fallahi P, Mosca M, Ferrari SM, Ruffilli I, Corti A, Panicucci E, Neri R, Bombardieri S. Prevalence of thyroid dysfunctions in systemic lupus erythematosus. Metabolism. 2010 Jun;59(6):896-900.
142. Antonelli A, Ferri C, Ferrari SM, Colaci M, Sebastiani M, Zignego AL, Ghiri E, Goglia F, Fallahi P. High levels of circulating N-terminal pro-brain natriuretic peptide in patients with hepatitis C. J Viral Hepat. 2010 Dec;17(12):851-3.
143. Antonelli A, Ferri C, Ferrari SM, Ghiri E, Goglia F, Pampana A, Bruschi F, Fallahi P. Serum levels of proinflammatory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor alpha in mixed cryoglobulinemia. Arthritis Rheum. 2009 Dec;60(12):3841-3847.
144. Galetta F, Franzoni F, Cervetti G, Regoli F, Fallahi P, Tocchini L, Carpi A, Antonelli A, Petrini M, Santoro G. In vitro and in vivo study on the antioxidant activity of dexrazoxane. Biomed Pharmacother. 2010;64(4):259-263.
145. Antonelli A, Ferri C, Ferrari SM, Ghiri E, Marchi S, Sebastiani M, Fallahi P. Serum Concentrations of Interleukin 1{beta}, CXCL10, and Interferon-{gamma} in Mixed Cryoglobulinemia Associated with Hepatitis C Infection. J Rheumatol. 2010 Jan;37(1):91-97.
146. Antonelli A, Mosca M, Fallahi P, Neri R, Ferrari SM, D’Ascanio A, Ghiri E, Carli L, Miccoli P, Bombardieri S. Thyroid Cancer in Systemic Lupus Erythematosus: A Case-Control Study. J Clin Endocrinol Metab. 2010 Jan;95(1):314-318.
147. Galetta F, Franzoni F, Fallahi P, Tocchini L, Graci F, Carpi A, Antonelli A, Santoro G. Effect of telmisartan on QT interval variability and autonomic control in hypertensive patients with left ventricular hypertrophy. Biomed Pharmacother. 2010 Oct;64(8):516-520.
148. Antonelli A, Ferrari SM, Fallahi P, Ghiri E, Crescioli C, Romagnani P, Vitti P, Serio M, Ferrannini E. Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: Modulation by peroxisome proliferator-activated receptor-gamma agonists. Cytokine. 2010 Jun;50(3):260-267.
149. Antonelli A, Ferri C, Ferrari SM, Marchi S, De Bortoli N, Sansonno D, Chiavacci C, Ferrannini E, Fallahi P. N-Terminal Pro-Brain Natriuretic Peptide and Tumor Necrosis Factor-alpha Both Are Increased in Patients With Hepatitis C. J Interferon Cytokine Res. 2010 May;30(5):359-363.
150. Galetta F, Franzoni F, Fallahi P, Tocchini L, Graci F, Gaddeo C, Rossi M, Cini G, Carpi A, Santoro G, Antonelli A. Changes in autonomic regulation and ventricular repolarization induced by subclinical hyperthyroidism. Biomed Pharmacother. 2010 Oct;64(8):546-549.
151. Antonelli A, Ferri C, Ferrari SM, Sebastiani M, Colaci M, Ruffilli I, Fallahi P. New targeted molecular therapies for dedifferentiated thyroid cancer. J Oncol. 2010;2010:921682.
152. Galetta F, Franzoni F, Bernini G, Poupak F, Carpi A, Cini G, Tocchini L, Antonelli A, Santoro G. Cardiovascular complications in patients with pheochromocytoma: A mini-review. Biomed Pharmacother. 2010 Sep; 64(7):505-509.
153. Antonelli A, Ferri C, Ferrari SM, Colaci M, Giuggioli D, Fallahi P. Induction of CXCL10 secretion by interferon-gamma and tumour necrosis factor-alpha and its inhibition by peroxisome proliferator-activated receptor-gamma agonists in cultured scleroderma fibroblasts. Br J Dermatol. 2010 Sep;163(3):650-1.
154. Antonelli A, Ferrari SM, Frascerra S, Pupilli C, Mancusi C, Metelli MR, Orlando C, Ferrannini E, Fallahi P. CXCL9 and CXCL11 Chemokines Modulation by Peroxisome Proliferator-Activated Receptor-{alpha} Agonists Secretion in Graves’ and Normal Thyrocytes. J Clin Endocrinol Metab. 2010 Dec;95(12):E413-20.
155. Antonelli A, Ferri C, Ferrari SM, De Marco S, Di Domenicantonio A, Centanni M, Pupilli C, Villa E, Menichetti F, Fallahi P. Interleukin-1β, C-X-C Motif Ligand 10, and Interferon-Gamma Serum Levels in Mixed Cryoglobulinemia With or Without Autoimmune Thyroiditis. J Interferon Cytokine Res. 2010 Nov;30(11):835-42.
156. Villa E, Karampatou A, Cammà C, Di Leo A, Luongo M, Ferrari A, Petta S, Losi L, Taliani G, Trande P, Lei B, Graziosi A, Bernabucci V, Critelli R, Pazienza P, Rendina M, Antonelli A, Francavilla A. Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. Gastroenterology. 2011 Mar;140(3):818-29.
157. Nicolini A, Ferrari P, Duffy MJ, Antonelli A, Rossi G, Metelli MR, Fulceri F, Anselmi L, Conte M, Berti P, Miccoli P. Intensive risk-adjusted follow-up with the CEA, TPA, CA19.9, and CA72.4 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrences: effect on survival. Arch Surg. 2010 Dec; 145(12):1177-83.
158. Antonelli A, Bocci G, La Motta C, Ferrari SM, Fallahi P, Fioravanti A, Sartini S, Minuto M, Piaggi S, Corti A, Alì G, Berti P, Fontanini G, Danesi R, Da Settimo F, Miccoli P. Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. J Clin Endocrinol Metab. 2011 Feb;96(2):E288-96.
159. Antonelli A, Ferri C, Ferrari SM, Di Domenicantonio A, Ferrari P, Pupilli C, Nicolini A, Zignego AL, Marchi S, Fallahi P. The presence of autoimmune thyroiditis in mixed cryoglobulinemia patients is associated with high levels of circulating Interleukin-6, but not of Tumor Necrosis Factor-alpha. Clin Exp Rheumatol. 2011 an-Feb;29(1 Suppl 64):S17-22.
160. Antonelli A, Ferrari SM, Fallahi P, Minuto M, Corrado A, Bruno R, Miccoli P. Medullary thyroid cancer: New targeted molecular therapies. 2010 Recent Patents on Endocrine, Metabolic and Immune Drug Discovery 4 (1):10-14.
161. Antonelli A, Ferrari SM, Fallahi P, Piaggi S, Paolicchi A, Franceschini SS, Salvi M, Ferrannini E. Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. Metabolism. 2011 Feb;60(2):277-83.
162. Antonelli A, Ferrari SM, Frascerra S, Corrado A, Pupilli C, Bernini G, Benvenga S, Ferrannini E, Fallahi P. Peroxisome proliferator-activated receptor α agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves’ disease. Exp Cell Res. 2011 Jul 1;317(11):1527-33.
163. Antonelli A, Ferrari SM, Frascerra S, Di Domenicantonio A, Nicolini A, Ferrari P, Ferrannini E, Fallahi P. Increase of Circulating CXCL9 and CXCL11 Associated with Euthyroid or Subclinically Hypothyroid Autoimmune Thyroiditis. J Clin Endocrinol Metab. 2011 Jun;96(6):1859-63.
164. Bocci G, Fioravanti A, La Motta C, Orlandi P, Canu B, Di Desidero T, Mugnaini L, Sartini S, Cosconati S, Frati R, Antonelli A, Berti P, Miccoli P, Da Settimo F, Danesi R. Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells. Biochem Pharmacol. 2011 Jun 1;81(11):1309-16.
165. Nicolini A, Ferrari P, Fini M, Borsari V, Fallahi P, Antonelli A, Berti P, Carpi A, Miccoli P. Stem cells: their role in breast cancer development and resistance to treatment. Curr Pharm Biotechnol. 2011 Feb 1;12(2):196-205.
166. Nicolini A, Ferrari P, Fini M, Borsari V, Fallahi P, Antonelli A, Carpi A, Miccoli P. Cancer stem cells: perspectives of new therapeutical approaches for breast cancer. Front Biosci (Schol Ed). 2011 Jun 1;3:1486-99.
167. Antonelli A, Ferrari SM, Frascerra S, Galetta F, Franzoni F, Corrado A, Miccoli M, Benvenga S, Paolicchi A, Ferrannini E, Fallahi P. Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10. Cytokine. 2011 Aug;55(2):288-93.
168. Antonelli A, Ferri C, Ferrari S, Mancusi C, Colaci M, Sebastiani M, Fallahi P. IFN-γ and TNF-α induce a different modulation of interleukin-6 in systemic sclerosis fibroblasts compared to healthy controls. Scand J Rheumatol. 2011 Nov;40(6):453-6.
169. Antonelli A, Ferri C, Ferrari SM, Ruffilli I, Colaci M, Frascerra S, Miccoli M, Franzoni F, Galetta F, Fallahi P. High Serum Levels of CXCL11 in Mixed Cryoglobulinemia Are Associated with Increased Circulating Levels of Interferon-{gamma}. J Rheumatol. 2011 Sep;38(9):1947-52.
170. Antonelli A, Fallahi P, Grosso M, Boni G, Minuto MN, Miccoli P. Lobectomy versus total thyroidectomy in children with post-Chernobyl thyroid cancer: a 15 year follow-up. Endocrine. 2011 Dec;40(3):432-6.
171. Antonelli A, Miccoli P, Materazzi G, Minuto M, Fallahi P, Ferrari SM, Berti P. The Role of Total Thyroidectomy in the Initial Treatment of Well-differentiated Follicular-cell-derived Thyroid Carcinomas. European Endocrinology – Thyroid Disorders, 2011;6(1):73-6.
172. Antonelli A, Fallahi P, Ulisse S, Ferrari SM, Minuto M, Saraceno G, Santini F, Mazzi V, D’Armiento M, Miccoli P. New Targeted Therapies for Anaplastic Thyroid Cancer. Anticancer Agents Med Chem. 2012 Jan 1;12(1):87-93.
173. Antonelli A, Ferrari SM, Frascerra S, Ruffilli I, Gelmini S, Minuto M, Pupilli C, Miccoli P, Sellari-Franceschini S, Ferrannini E, Fallahi P. Peroxisome proliferator-activated receptor-α agonists modulate CXCL9 and CXCL11 chemokines in Graves’ ophthalmopathy fibroblasts and preadipocytes. Mol Cell Endocrinol. 2012 Feb 26;349(2):255-61.
174. Antonelli A, Ferri C, Ferrari SM, Frascerra S, Ruffilli I, Caponi L, Ulisse S, Miccoli M, Miccoli P, Fallahi P. High Levels of Circulating Chemokine (C-X-C motif) Ligand 11 Are Associated with Euthyroid or Subclinically Hypothyroid Autoimmune Thyroiditis and with Chemokine (C-X-C Motif) Ligand 10. J Interferon Cytokine Res. 2012 Feb;32(2):74-80.
175. Antonelli A, Fallahi P, Ferrari SM, Sebastiani M, Manfredi A, Mazzi V, Fabiani S, Centanni M, Marchi S, Ferri C. Circulating CXCL11 and CXCL10 are increased in hepatitis C-associated cryoglobulinemia in the presence of autoimmune thyroiditis. Mod Rheumatol. 2012 Sep;22(5):659-67. Epub 2011 Dec 14.
176. Antonelli A, Fallahi P, Ferrari SM, Di Domenicantonio A, Moreno M, Lanni A, Goglia F. 3,5-diiodo-l-thyronine increases resting metabolic rate and reduces body weight without undesirable side effects. J Biol Regul Homeost Agents. 2011 Oct-Dec;25(4):655-60.
177. Antonelli A, Fallahi P, Ferrari SM, Mancusi C, Colaci M, Santarpia L, Ferri C. RET TKI: Potential Role in Thyroid Cancers. Curr Oncol Rep. 2012 Apr;14(2):97-104.
178. Antonelli A, Bocci G, La Motta C, Ferrari SM, Fallahi P, Ruffilli I, Di Domenicantonio A, Fioravanti A, Sartini S, Minuto M, Piaggi S, Corti A, Alì G, Di Desidero T, Berti P, Fontanini G, Danesi R, Da Settimo F, Miccoli P. CLM94, a Novel Cyclic Amide with Anti-VEGFR-2 and Antiangiogenic Properties, Is Active against Primary Anaplastic Thyroid Cancer in Vitro and in Vivo. J Clin Endocrinol Metab. 2012 Apr;97(4):E528-36.
179. Antonelli A, Fallahi P, Ferrari SM, Ruffilli I, Santini F, Minuto M, Galleri D, Miccoli P. New targeted therapies for thyroid cancer. Current Genomics, 2011; 12:626-631.
180. Nicolini A, Ferrari P, Fallahi P, Antonelli A. An iron regulatory gene signature in breast cancer: More than a prognostic genetic profile? Future Oncology. Feb 2012; 8(2):131-134.
181. Antonelli A, Ferrari SM, Frascerra S, Ruffilli I, Pupilli C, Bernini G, Sellari Franceschini S, Gelmini S, Ferrannini E, Fallahi P. β (CCL2) and α (CXCL10) chemokines modulation by cytokines and by peroxisome proliferator activated receptor-α agonists in Graves’ ophthalmopathy. J Endocrinol. 2012 May;213(2):183-91.
182. Antonelli A, Fallahi P, Ferrari SM, Giuggioli D, Colaci M, Di Domenicantonio A, Ferri C. Systemic Sclerosis Fibroblasts Show Specific Alterations of Interferon-γ and Tumor Necrosis Factor-α-induced Modulation of Interleukin 6 and Chemokine Ligand 2. J Rheumatol. 2012 May;39(5):979-85.
183. Fallahi P, Ferri C, Ferrari SM, Corrado A, Sansonno D, Antonelli A. Cytokines and HCV-Related Disorders. Clin Dev Immunol. 2012;2012:468107.
184. Fazzi P, Manni E, Cristofani R, Cei G, Piazza S, Calabrese R, Antonelli A, Siciliano G, Barachini P, Carpi A. Thalidomide for improving cutaneous and pulmonary sarcoidosis in patients resistant or with contraindications to corticosteroids. Biomed and Pharmacother. June 2012; 66(4):300-307.
185. Antonelli A, Ferrari SM, Fallahi P, Piaggi S, Di Domenicantonio A, Galleri D, Santarpia L, Basolo F, Ferrannini E, Miccoli P. Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer. Cytokine. 2012 Aug;59(2):218-22.
186. Antonelli A, Fallahi P, Ferrari SM, Ghiadoni L, Virdis A, Mancusi C, Centanni M, Taddei S, Ferrannini E. High serum levels of CXC (CXCL10) and CC (CCL2) chemokines in untreated essential hypertension. Int J Immunopathol Pharmacol. 2012 Apr-Jun;25(2):387-95.
187. Antonelli A, Ferri C, Ferrari SM, Di Domenicantonio A, Mancusi C, Marchi S, De Bortoli N, Metelli MR, Bruschi F, Fallahi P. Hepatitis C is associated with high levels of circulating N-terminal pro-brain natriuretic peptide and interleukin-6. European Journal of Inflammation. 2012 Jan-Apr;10(1):133-138.
188. Ferri C, Sebastiani M, Antonelli A, Colaci M, Manfredi A, Giuggioli D. Current treatment of hepatitis C-associated rheumatic diseases. Arthritis Res Ther. 2012 Jun 25;14(3):215.
189. Antonelli A, Fallahi P, Ferrari SM, Corrado A, Sebastiani M, Manfredi A, Frascerra S, Miccoli M, Zigniego AL, Ferrannini E, Ferri C. Chemokine (CXC motif) ligand 9 serum levels in mixed cryoglobulinemia are associated with circulating levels of IFN-γ and TNF-α. Clin Exp Rheumatol. 2012 Nov-Dec;30(6):864-70.
190. Antonelli A, Fallahi P, Ferrari SM, Frascerra S, Corrado A, Colaci M, Manfredi A, Maccheroni, M, Sansonno D, Zignego AL, Centanni M, Ferri C. Patients with mixed cryoglobulinemia and HCV infection, in presence or absence of autoimmune thyroiditis, have high serum levels of (CXC motif) ligand (CXCL)9 and CXCL11 chemokines. European Journal of Inflammation. 2012; 10(3):347-455.
191. Antonelli A, Ferri C, Ferrari SM, Colaci M, Ruffilli I, Sebastiani M, Fallahi P. Peroxisome proliferator-activated receptor γ agonists reduce cell proliferation and viability and increase apoptosis in systemic sclerosis fibroblasts. Br J Dermatol. 2013 Jan;168(1):129-35.
192. Antonelli A, Ferrari SM, Mancusi C, Mazzi V, Pupilli C, Centanni M, Ferri C, Ferrannini E, Fallahi P. Interferon-α, -β and -γ induce CXCL11 secretion in human thyrocytes: Modulation by peroxisome proliferator-activated receptor γ agonists. Immunobiology. 2013 May;218(5):690-5.
193. Baldini E, Sorrenti S, D’Armiento E, Guaitoli E, Morrone S, D’Andrea V, Gnessi L, Moretti C, Antonelli A, Catania A, De Antoni E, Ulisse S. Effects of the Aurora kinases pan-inhibitor SNS-314 mesylate on anaplastic thyroid cancer derived cell lines. Clin Ter. 2012 Sep;163(5):e307-13.
194. Antonelli, A. CXC-Chemokines and Thyroid Associated Autoimmunity. Journal of Thyroid Disorders & Therapy, 2012 vol. 01, no. 04.
195. Galetta F, Carpi A, Abraham N, Guidotti E, Russo MA, Camici M, Antonelli A, Franzoni F, Santoro G. Age related cardiovascular dysfunction and effects of physical activity. Front Biosci (Elite Ed). 2012 Jun 1;4:2617-37.
196. Cossu A, Ferrannini E, Fallahi P, Antonelli A, Sechi LA. Antibodies recognizing specific Mycobacterium avium subsp. paratuberculosis’s MAP3738c protein in type 1 diabetes mellitus children are associated with serum Th1 (CXCL10) chemokine. Cytokine. 2013 Feb;61(2):337-9.
197. Antonelli A, Fallahi P, Ferrari SM, Frascerra S, Mancusi C, Colaci M, Manfredi A, Sansonno D, Zignego AL, Ferri C. High circulating chemokines (C-X-C motif) ligand 9, and (C-X-C motif) ligand 11, in hepatitis C-associated cryoglobulinemia. Int J Immunopathol Pharmacol. 2013 Jan-Mar;26(1):49-57.
198. Giunti S, Antonelli A, Amorosi A, Santarpia L. Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma. Int J Endocrinol. 2013;2013:803171.
199. Baldini E, Sorrenti S, Di Gioia C, De Vito C, Antonelli A, Gnessi L, Carbotta G, D’Armiento E, Miccoli P, De Antoni E, Ulisse S. Cervical lymph node metastases from thyroid cancer: does thyroglobulin and calcitonin measurement in fine needle aspirates improve the diagnostic value of cytology? BMC Clin Pathol. 2013 Feb 19;13:7.
200. Antonelli A, Fallahi P, Ferrari SM, Corrado A, Sebastiani M, Giuggioli D, Miccoli M, Zignego AL, Sansonno D, Marchi S, Ferri C. Parallel increase of circulating CXCL11 and CXCL10 in mixed cryoglobulinemia, while the proinflammatory cytokine IL-6 is associated with high serum Th2 chemokine CCL2. Clin Rheumatol. 2013 Aug;32(8):1147-54.
201. Carpi A, Cini G, Russo M, Antonelli A, Gaudio C, Galetta F, Franzoni F, Rossi G. Subclinical hyperthyroidism and cardiovascular manifestations: a reevaluation of the association. Intern Emerg Med. 2013 Apr;8 Suppl 1:S75-7.
202. Bruno RM, Sicari R, Corciu AI, Bianchini E, Faita F, Di Stefano R, Antonelli A, Ghiadoni L, Picano E. Non-cancer atherosclerotic effects associated with environmental and therapeutic radiation doses: The Chernobyl thyroid cancer children study. Int J Cardiol. 2013 Oct 9;168(4):4255-7 7.078
203. Antonelli A, Ferrari SM, Corrado A, Ferrannini E, Fallahi P. Increase of interferon-γ inducible α chemokine (C-X-C motif) ligand (CXCL)9 and CXCL11 serum levels in patients with active Graves’ disease, and modulation by methimazole therapy. Thyroid. 2013 Nov;23(11):1461-9.
204. Antonelli A, Fallahi P, Ferrari SM, Mancusi C, Giuggioli D, Colaci M, Ferri C. Incidence of thyroid disorders in systemic sclerosis: results from a longitudinal follow-up. J Clin Endocrinol Metab. 2013 Jul;98(7):E1198-202.
205. Giuggioli D, Manfredi A, Colaci M, Manzini CU, Antonelli A, Ferri C. Systemic sclerosis and cryoglobulinemia: Our experience with overlapping syndrome of scleroderma and severe cryoglobulinemic vasculitis and review of the literature. Autoimmun Rev. 2013 Sep;12(11):1058-63.
206. Fallahi P, Ferrari SM, Santini F, Corrado A, Materazzi G, Ulisse S, Miccoli P, Antonelli A. Sorafenib and Thyroid Cancer. BioDrugs. 2013 Dec;27(6):615-28.
207. Vita R, Mazzi V, Antonelli A, Benvenga S. Antithyroid medications and psychosis. Expert Opin Drug Saf. 2013 Nov;12(6):865-72.
208. Antonelli A, Fallahi P, Ferrari SM, Colaci M, Giuggioli D, Saraceno G, Benvenga S, Ferri C. Increased CXCL9 Serum Levels in Hepatitis C-Related Mixed Cryoglobulinemia, with Autoimmune Thyroiditis, Associated with High Levels of CXCL10. J Interferon Cytokine Res. 2013 Dec;33(12):739-45.
209. Ferrari SM, Fallahi P, Mancusi C, Colaci M, Manfredi A, Ferri C, Antonelli A. HCV-related autoimmune disorders in HCV chronic infection. Clin Ter. 2013 Jul-Aug;164(4):e305-12.
210. Fallahi P, Ferrari SM, Giuggioli D, Corrado A, Fabiani S, Marchi S, Ferri C, Antonelli A. Mixed cryoglobulinemia and thyroid autoimmune disorders. Clin Ter. 2013 Jul-Aug;164(4):e337-41.
211. Baldini E, Tuccilli C, Prinzi N, Sorrenti S, Antonelli A, Gnessi L, Catania A, Moretti C, Mocini R, Carbotta G, Morrone S, Persechino S, Redler A, De Antoni E, D’ Armiento M, Ulisse S. The dual Aurora kinase inhibitor ZM447439 prevents anaplastic thyroid cancer cell growth and tumorigenicity. J Biol Regul Homeost Agents. 2013 Jul-Sep;27(3):705-15.
212. Antonelli A, Ferrari SM, Giuggioli D, Ferrannini E, Ferri C, Fallahi P. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev. 2014 Mar;13(3):272-80
213. Fallahi P, Ferrari SM, Colaci M, Ruffilli I, Vita R, Azzi A, Ferri C, Antonelli A, Ferrannini E. Hepatitis C virus infection and type 2 diabetes. Clin Ter. 2013 Sep-Oct;164(5):e393-404.
214. Fallahi P, Di Domenicantonio A, Mazzi V, Santini F, Fabiani S, Sebastiani M, Zignego AL, Ferri C, Antonelli A. Hepatitis C virus and type 1 diabetes. Clin Ter. 2013 Sep-Oct;164(5):e437-44.
215. Antonelli A, Bocci G, Fallahi P, La Motta C, Martina Ferrari S, Mancusi C, Fioravanti A, Di Desidero T, Sartini S, Corti A, Piaggi S, Materazzi G, Spinelli C, Fontanini G, Danesi R, Da Settimo F, Miccoli P. CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. J Clin Endocrinol Metab. 2014 Apr;99(4):E572-81
216. Fallahi P, Ferrari SM, Giuggioli D, Manfredi A, Mancusi C, Fabiani S, Centanni M, Marchi S, Ferri C, Antonelli A. Thyroid involvement in hepatitis C – Associated mixed cryoglobulinemia. Hormones (Athens). 2014 Jan;13(1):16-23.
217. Sartini S, Coviello V, Bruno A, La Pietra V, Marinelli L, Simorini F, Taliani S, Salerno S, Marini AM, Fioravanti A, Orlandi P, Antonelli A, Da Settimo F, Novellino E, Bocci G, La Motta C. Structure-Based Optimization of Tyrosine Kinase Inhibitor CLM3. Design, Synthesis, Functional Evaluation, and Molecular Modeling Studies. J Med Chem. 2014 Feb 27;57(4):1225-35.
218. Antonelli A, Ferrari SM, Corrado A, Ferrannini E, Fallahi P. CXCR3, CXCL10 and type 1 diabetes. Cytokine Growth Factor Rev. 2014 Feb;25(1):57-65
219. Martinucci I, de Bortoli N, Savarino E, Piaggi P, Bellini M, Antonelli A, Savarino V, Frazzoni M, Marchi S. Esophageal baseline impedance levels in patients with pathophysiological characteristics of functional heartburn. Neurogastroenterol Motil. 2014 Apr;26(4):546-555
220. Fallahi P, Ferrari SM, Mazzi V, Vita R, Benvenga S, Antonelli A. Personalization of targeted therapy in advanced thyroid cancer. Curr Genomics. 2014 Jun;15(3):190-202.
221. Fallahi P, Giannini R, Miccoli P, Antonelli A, Basolo F. Molecular diagnostics of fine needle aspiration for the presurgical screening of thyroid nodules. Curr Genomics. 2014 Jun;15(3):171-7.
222. Antonelli A. “Molecular profiling and ways towards personalized medicine in advanced differentiated thyroid cancer”. Curr Genomics. 2014 Jun;15(3):161.
223. Ferrari SM, Antonelli A, Di Domenicantonio A, Manfredi A, Ferri C, Fallahi P. Modulatory Effects of Peroxisome Proliferator-Activated Receptor-γ on CXCR3 Chemokines. Recent Pat Inflamm Allergy Drug Discov. 2014 Jun 23;8(2):132-8.
224. Fallahi P, Ferrari SM, Corrado A, Giuggioli D, Ferri C, Antonelli A. Targeting Chemochine (C-X-C motif) Receptor 3 in Thyroid Autoimmunity. Recent Pat Endocr Metab Immune Drug Discov. 2014 Jun 23; 8(2);95-101.
225. Antonelli A, Bocci G, La Motta C, Ferrari SM, Fallahi P, Corrado A, Fioravanti A, Sartini S, Orlandi P, Piaggi S, Corti A, Materazzi G, Galleri D, Ulisse S, Fontanini G, Danesi R, Da Settimo F, Miccoli P. CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo. Mol Cell Endocrinol. 2014 Jun 12;393(1-2):56-64.
226. Vita R, Fallahi P, Antonelli A, Benvenga S. The administration of l-thyroxine as soft gel capsule or liquid solution. Expert Opin Drug Deliv. 2014 Jul;11(7):1103-11.
227. Fallahi P, Ferrari SM, Vita R, Di Domenicantonio A, Corrado A, Benvenga S, Antonelli A. Thyroid dysfunctions induced by tyrosine kinase inhibitors. Expert Opin Drug Saf. 2014 Jun;13(6):723-33.
228. Corrado A, Ferrari SM, Ferri C, Ferrannini E, Antonelli A, Fallahi P. Type 1 diabetes and (C-X-C motif) ligand (CXCL) 10 chemokine. Clin Ter. 2014;165(2):e181-5.
229. Mancusi C, Di Domenicantonio A, Politti U, Giuggioli D, Antonelli A, Ferri C, Fallahi P. [The alpha chemokine “Interferon gamma-induced protein 10” (IP-10) in Graves’ disease]. Clin Ter. 2014;165(2):e174-80. Italian.
230. Ruffilli I, Ferrari SM, Colaci M, Ferri C, Fallahi P, Antonelli A. IP-10 in Autoimmune Thyroiditis. Horm Metab Res. 2014 Aug;46(9):597-602
231. Di Domenicantonio A, Politti U, Giuggioli D, Antonelli A, Ferri C, Fallahi P. [The alpha chemokine “Interferon gamma-induced protein 10 (IP-10) in Graves’ disease and Graves’ophthalmopathy.] Clin Ter. 2014 May-Jun;165(3):e230-e236.
232. Ruffilli I, Ferrari SM, Colaci M, Ferri C, Politti U, Antonelli A, Fallahi P. [CXCR3 and CXCL10 in autoimmune thyroiditis.] Clin Ter. 2014 May-Jun;165(3):e237-e242.
233. Baldini E, Tuccilli C, Prinzi N, Sorrenti S, Antonelli A, Gnessi L, Morrone S, Moretti C, Bononi M, Arlot-Bonnemains Y, D’Armiento M, Ulisse S. Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines. Endocr Relat Cancer. 2014 Oct;21(5):797-811.
234. Ferrari SM, Fallahi P, La Motta C, Bocci G, CorradoA, Materazzi G, Galleri D, Piaggi S, Danesi R, Da Settimo F, Miccoli P, Antonelli A. Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro. Surgery 2014 Aug 20. 156(5):1167-1176.
235. Antonelli A, Ferrari SM, Corrado A, Franceschini SS, Gelmini S, Ferrannini E, Fallahi P. Extra-ocular muscle cells from patients with Graves’ ophthalmopathy secrete α (CXCL10) and β (CCL2) chemokines under the influence of cytokines that are modulated by PPARγ. Autoimmun Rev. 2014 Aug 27. 13(11):1160-6.
236. Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P. Autoimmune thyroid disorders. Autoimmun Rev. 2015 Feb;14(2):174-180.
237. Zignego AL, Gragnani L, Piluso A, Sebastiani M, Giuggioli D, Fallahi P, Antonelli A, Ferri C. Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection. Expert Rev Clin Immunol. 2015 Jan;11(1):15-31.
238. Fallahi P, Corrado A, Di Domenicantonio A, Frenzilli G, Antonelli A. CXCR3, CXCR5, CXCR6, and CXCR7 in Diabetes. Curr Drug Targets. Epub 2014 Dec 29. 2016;17(5):515-9.
239. Ferrari SM, Fallahi P, Vita R, Antonelli A, Benvenga S. Peroxisome Proliferator-Activated Receptor- γ in Thyroid Autoimmunity. PPAR Res. 2015;2015:232818.
240. Fallahi P, Mazzi V, Vita R, Ferrari SM, Materazzi G, Galleri D, Benvenga S, Miccoli P, Antonelli A. New Therapies for Dedifferentiated Papillary Thyroid Cancer. Int J Mol Sci. 2015 Mar 17;16(3):6153-6182.
241. Baldini E, Tuccilli C, Prinzi N, Sorrenti S, Falvo L, De Vito C, Catania A, Tartaglia F, Mocini R, Coccaro C, Alessandrini S, Barollo S, Mian C, Antonelli A, De Antoni E, D’Armiento M, Ulisse S. Deregulated expression of aurora kinases is not a prognostic biomarker in papillary thyroid cancer patients. PLoS One. 2015 Mar 25;10(3):e0121514.
242. Ferri C, Sebastiani M, Giuggioli D, Colaci M, Fallahi P, Piluso A, Antonelli A, Zignego AL. Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin’s lymphoma, and cancer. World J Hepatol. 2015 Mar 27;7(3):327-43.
243. Antonelli A, Ferrari SM, Fallahi P. The role of the Th1 chemokine CXCL10 in vitiligo. Ann Transl Med. 2015 May;3(Suppl 1):S16.
244. Corrado A, Ferrari SM, Politti U, Mazzi V, Miccoli M, Materazzi G, Antonelli A, Ulisse S, Fallahi P, Miccoli P. Aggressive thyroid cancer: targeted therapy with sorafenib. Minerva Endocrinol. 2017 Mar;42(1):64-76. Epub 2015 Jun 26
245. Fallahi P, Ferrari SM, Di Bari F, Materazzi G, Benvenga S, Miccoli P, Antonelli A. Cabozantinib in Thyroid Cancer. Recent Pat Anticancer Drug Discov. 2015;10(3):259-69.
246. Ferrari SM, Politti U, Spisni R, Materazzi G, Baldini E, Ulisse S, Miccoli P, Antonelli A, Fallahi P. Sorafenib in the treatment of thyroid cancer. Expert Rev Anticancer Ther. 2015 Jul 7:1-12.
247. Fallahi P, Di Bari F, Ferrari SM, Spisni R, Materazzi G, Miccoli P, Benvenga S, Antonelli A. Selective use of vandetanib in the treatment of thyroid cancer. Drug Des Devel Ther. 2015 Jul 3;9:3459-70.
248. Fallahi P, Ferrari SM, Giuggioli D, Sebastiani M, Colaci M, Ferri C, Antonelli A. Chemokines in the pathogenesis and as therapeutical markers and targets of HCV chronic infection, and HCV extrahepatic manifestations. Curr Drug Targets. 2015 Aug 3. 2017;18:786-793.
249. Ferrari SM, Ruffilli I, Colaci M, Antonelli A, Ferri C, Fallahi P. CXCL10 in psoriasis. Adv Med Sci. 2015 Aug 12;60(2):349-354.
250. Fallahi P, Ferrari SM, La Motta C, Materazzi G, Bocci G, Da Settimo F, Miccoli P, Antonelli A. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation. Endocrine. 2016 Jul;53(1):136-44.
251. Giuggioli D, Sebastiani M, Colaci M, Fallahi P, Gragnani L, Zignego AL, Antonelli A, Ferri C. Treatment of HCV-related mixed cryoglobulinemia. Curr Drug Targets. 2017;18 (7):794-802.
252. Sebastiani M, Giuggioli D, Colaci M, Fallahi P, Gragnani L, Antonelli A, Zignego AL, Ferri C. HCV-related rheumatic manifestations and therapeutic strategies. Curr Drug Targets. 2015 Sep 6. 2017;18:803-810.
253. Antonelli A, Ferri C, Ferrari SM, Di Domenicantonio A, Giuggioli D, Galleri D, Miccoli P, Fallahi P. Increased risk of papillary thyroid cancer in systemic sclerosis associated with autoimmune thyroiditis. Rheumatology (Oxford). 2016 Mar;55(3):480-4.
254. Ferrari SM, La Motta C, Sartini S, Baldini E, Materazzi G, Politti U, Ruffilli I, Ulisse S, Miccoli P, Antonelli A, Fallahi P. Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer. Mini Rev Med Chem. 2016;16(2):86-93
255. Antonelli A, Pistello M. New Therapies, Markers and Therapeutic Targets in HCV Chronic Infection, and HCV Extrahepatic Manifestations. Curr Drug Targets. Epub 2015 Nov 1. 2017;18(7):752-755.
256. Ferrari SM, Fallahi P, Politti U, Materazzi G, Baldini E, Ulisse S, Miccoli P, Antonelli A. Molecular Targeted Therapies of Aggressive Thyroid Cancer. Front Endocrinol (Lausanne). 2015 Nov 20;6:176. eCollection 2015. Review.
257. Fallahi P, Ferrari SM, Giuggioli D, Ferri C, Antonelli A. Application of agents against interferon-gamma-dependent chemokines in immunotherapy. Letters in Drug Design and Discovery. 2015;12(9):696-703.
258. Fallahi P, Ferrari SM, Antonelli A. Oral L-thyroxine liquid versus tablet in patients with hypothyroidism without malabsorption: a prospective study. Endocrine. 2016;52(3):597-601.
259. Borrelli N, Ugolini C, Giannini R, Antonelli A, Giordano M, Sensi E, Torregrossa L, Fallahi P, Miccoli P, Basolo F. Role of gene expression profiling in defining indeterminate thyroid nodules in addition to BRAF analysis. Cancer Cytopathol. 2016 May;124(5):340-9.
260. Benvenga S, Antonelli A, Vita R. Thyroid nodules and thyroid autoimmunity in the context of environmental pollution. Rev Endocr Metab Disord. 2015 Dec;16(4):319-40.
261. Ferrari SM, Materazzi G, Baldini E, Ulisse S, Miccoli P, Antonelli A, Fallahi P. Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer. Curr Med Chem. 2016;23(7):636-49.
262. Fallahi P, Ferrari SM, Elia G, Nasini F, Colaci M, Giuggioli D, Vita R, Benvenga S, Ferri C, Antonelli A. Novel Therapies for Thyroid Autoimmune Diseases. Expert Rev Clin Pharmacol. 2016 Mar 8:1-9.
263. Vita R, Lapa D, Trimarchi F, Vita G, Fallahi P, Antonelli A, Benvenga S. Certain HLA alleles are associated with stress-triggered Graves’ disease and influence its course. Endocrine. 2017 Jan;55(1):93-100.
264. Fallahi P, Ferrari SM, Ruffilli I, Elia G, Giuggioli D, Colaci M, Ferri C, Antonelli A. Incidence of thyroid disorders in mixed cryoglobulinemia: Results from a longitudinal follow-up. Autoimmun Rev. 2016 Jul;15(7):747-51.
265. Fallahi P, Ferrari SM, Ruffilli I, Antonelli A. Reversible normalisation of serum TSH levels in patients with autoimmune atrophic gastritis who received L-T4 in tablet form after switching to an oral liquid formulation: a case series. BMC Gastroenterol. 2016 Feb 24;16(1):22.
266. Fallahi P, Ferrari SM, Camastra S, Politti U, Ruffilli I, Vita R, Navarra G, Benvenga S, Antonelli A. TSH Normalization in Bariatric Surgery Patients After the Switch from L-Thyroxine in Tablet to an Oral Liquid Formulation. Obes Surg. 2017 Jan;27(1):78-82.
267. Fallahi P, Ferrari SM, Ruffilli I, Ragusa F, Biricotti M, Materazzi G, Miccoli P, Antonelli A. Advancements in the treatment of hypothyroidism with L-T4 liquid formulation or soft gel capsule: an update. Expert Opin Drug Deliv. 2016 Aug 30:1-9.
268. Fallahi P, Ferrari SM, Marchi S, De Bortoli N, Ruffilli I, Antonelli A. Patients with lactose intolerance absorb liquid levothyroxine better than tablet levothyroxine. Endocrine. 2017 Jul;57(1):175-178.
269. Fallahi P, Ferrari SM, Ruffilli I, Elia G, Biricotti M, Vita R, Benvenga S, Antonelli A. The association of other autoimmune diseases in patients with autoimmune thyroiditis: Review of the literature and report of a large series of patients. Autoimmun Rev. 2016;15(12):1125-1128.
270. Ferri C, Ramos-Casals M, Zignego AL, Arcaini L, Roccatello D, Antonelli A, Saadoun D, Desbois AC, Sebastiani M, Casato M, Lamprecht P, Mangia A, Tzioufas AG, Younossi ZM, Cacoub P; ISG-EHCV coauthors. International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmun Rev. Autoimmun Rev. 2016 Dec;15(12):1145-1160 Review.
271. Fallahi P, Ferrari SM, Baldini E, Biricotti M, Ulisse S, Materazzi G, Miccoli P, Antonelli A. The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer. Expert Rev Anticancer Ther. 2016 Nov;16(11):1109-1118.
272. Fallahi P, Ferrari SM, Antonelli A. In patients with subclinical hypothyroidism while in therapy with tablet l-t4, the liquid l-t4 formulation is more effective in restoring euthyroidism. Endocr Pract. 2017 Feb;23(2):170-174.
273. Giuggioli D, Colaci M, Cassone G, Fallahi P, Lumetti F, Spinella A, Campomori F, Manfredi A, Manzini CU, Antonelli A, Ferri C. Serum 25-OH vitamin D levels in systemic sclerosis: analysis of 140 patients and review of the literature. Clin Rheumatol. 2017 Mar;36(3):583-590.
274. Baldini E, Tuccilli C, Arlot-Bonnemains Y, Chesnel F, Sorrenti S, De Vito C, Catania A, D’Armiento E, Antonelli A, Fallahi P, Watutantrige-Fernando S, Tartaglia F, Barollo S, Mian C, Bononi M, Arceri S, Mascagni D, Vergine M, Pironi D, Monti M, Filippini A, Ulisse S. Deregulated expression of VHL mRNA variants in papillary thyroid cancer. Mol Cell Endocrinol. 2017 Mar 5;443:121-127.
275. Fallahi P, Ferrari SM, Ruffilli I, Elia G, Miccoli M, Sedie AD, Riente L, Antonelli A. Increased incidence of autoimmune thyroid disorders in patients with psoriatic arthritis: a longitudinal follow-up study. Immunol Res. 2017 Jun;65(3):681-686.
276. Zignego AL, Ramos-Casals M, Ferri C, Saadoun D, Arcaini L, Roccatello D, Antonelli A, Desbois AC, Comarmond C, Gragnani L, Casato M, Lamprecht P, Mangia A, Tzioufas AG, Younossi ZM, Cacoub P; ISG-EHCV. International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. Autoimmun Rev. 2017 May;16(5):523-541 Review.
277. Tuccilli C, Baldini E, Arlot-Bonnemains Y, Chesnel F, Sorrenti S, De Vito C, D’Armiento E, Antonelli A, Fallahi P, Watutantrige S, Tartaglia F, Barollo S, Mian C, Arcieri S, Mascagni D, Pironi D, Bononi M, Vergine M, Monti M, Filippini A, Ulisse S. Expression and prognostic value of the cell polarity PAR complex members in thyroid cancer. Int J Oncol. 2017 Mar 8;50(4):1413-1422.
278. Ferrari SM, Fallahi P, Antonelli A, Benvenga S. Environmental Issues in Thyroid Diseases. Front Endocrinol (Lausanne). 2017;8:50. doi: 10.3389/fendo.2017.00050. eCollection 2017. Review.
279. Antonelli A, Fallahi P, Di Bari F, Giuggioli D, Ferrari SM, Ferri C. Fatigue in patients with systemic sclerosis and hypothyroidism. A review of the literature and report of our experience. Clin Exp Rheumatol. 2017 Apr 4. [Epub ahead of print].
280. Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Salvi M, Goldberg RA, Gigantelli JW, Couch SM, Shriver EM, Hayek BR, Hink EM, Woodward RM, Gabriel K, Magni G, Douglas RS. Teprotumumab for Thyroid-Associated Ophthalmopathy. N Engl J Med. 2017 May 4;376(18):1748-1761.
281. Le Donne M, Mento C, Settineri S, Antonelli A, Benvenga S. Postpartum Mood Disorders and Thyroid Autoimmunity. Front Endocrinol (Lausanne). 2017 May 4;8:91. doi: 10.3389/fendo.2017.00091. eCollection 2017.
282. Antonelli A, La Motta C. Novel therapeutic clues in thyroid carcinomas: The role of targeting cancer stem cells. Med Res Rev. 2017 Jun 6. doi: 10.1002/med.21448. [Epub ahead of print] Review.
283. Ferrari SM, Elia G, Virili C, Centanni M, Antonelli A, Fallahi P. Systemic Lupus Erythematosus and Thyroid Autoimmunity. Front Endocrinol (Lausanne). 2017 Jun 19;8:138.
284. Ruffilli I, Ragusa F, Benvenga S, Vita R, Antonelli A, Fallahi P, Ferrari SM. Psoriasis, Psoriatic Arthritis, and Thyroid Autoimmunity. Front Endocrinol (Lausanne). 2017 Jun 19;8:139. doi: 10.3389/fendo.2017.00139. eCollection 2017. Review.
285. Spinelli C, Rossi L, Piscioneri J, Strambi S, Antonelli A, Ferrari A, Massimino M, Miccoli P. Pediatric Differentiated Thyroid Cancer: When to Perform Conservative and Radical Surgery. Curr Pediatr Rev. 2016;12(4):247-252.
286. Ferrari SM, Fallahi P, Santaguida G, Virili C, Ruffilli I, Ragusa F, Centanni M, Antonelli A. Circulating CXCL10 is increased in non-segmental vitiligo, in presence or absence of autoimmune thyroiditis. Autoimmun Rev. 2017 Sep;16(9):946-950. Review.
287. Benvenga S, Vicchio T, Di Bari F, Vita R, Fallahi P, Ferrari SM, Catania S, Costa C, Antonelli A. Favorable effects of myo-inositol, selenomethionine or their combination on the hydrogen peroxide-induced oxidative stress of peripheral mononuclear cells from patients with Hashimoto’s thyroiditis: preliminary in vitro studies. Eur Rev Med Pharmacol Sci. 2017 Jun;21(2 Suppl):89-101.
288. Ferrari SM, Fallahi P, Di Bari F, Vita R, Benvenga S, Antonelli A. Myo-inositol and selenium reduce the risk of developing overt hypothyroidism in patients with autoimmune thyroiditis. Eur Rev Med Pharmacol Sci. 2017 Jun;21(2 Suppl):36-42.
289. Ferrari SM, Elia G, Piaggi S, Baldini E, Ulisse S, Miccoli M, Materazzi G, Antonelli A, Fallahi P. CCL2 is Modulated by Cytokines and PPAR-g in Anaplastic Thyroid Cancer. Anticancer Agents Med Chem. 2017 Jul 19. doi: 10.2174/1871520617666170719152349. [Epub ahead of print].
290. Ferri C, Colaci M, Fallahi P, Ferrari SM, Antonelli A, Giuggioli D. Thyroid Involvement in Hepatitis C Virus-Infected Patients with/without Mixed Cryoglobulinemia. Front Endocrinol (Lausanne). 2017 Jul 7;8:159. doi: 10.3389/fendo.2017.00159. eCollection 2017. Review.
291. Fallahi P, Ferrari SM, Santini E, Camastra S, Frenzilli G, Puccini M, Goglia F, Lanni A, Marchetti P, Antonelli A. Both 3,5-diiodo-L-thyronine (T2) and T3 modulate glucose-induced insulin secretion. J Biol Regul Homeost Agents. 2017 Apr-Jun;31(2):503-508.
292. Benvenga S, Papi G, Antonelli A. Refractory Hypothyroidism Due to Improper Storage of Levothyroxine Tablets. Front Endocrinol (Lausanne). 2017 Jul 10;8:155. doi: 10.3389/fendo.2017.00155. eCollection 2017.